Exogenous bovine thrombin as a biomarker of exposure and outcome

Expert Review of Molecular Diagnostics

Volumn 8, Issue 5, 2008, Pages 651-661

  Crean, Sheila M ^a   Michels, Shannon L ^a   Reynolds, Matthew W ^a  

^a UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

Adverse event; Formulation; Hemostasis; Hemostat; Iatrogenic immunization; Surgery; Thrombin

Indexed keywords

COSTASIS; FIBRIN; FIBRIN GLUE; FIBRINOGEN; FIBRINOPEPTIDE A; FLOSEAL; GELFOAM; HEMOSTATIC AGENT; IMMUNOGLOBULIN; PROTEIN ANTIBODY; PROTHROMBIN; PUTRESCINE; SEALANT; THROMBIN; THROMBIN JMI; THROMBOCYTE FACTOR 3; THROMBOCYTE FACTOR 5; THROMBOMODULIN; THROMBOSTAT; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ADENOIDECTOMY; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD VESSEL INJURY; BURN; CLINICAL TRIAL; COUGHING; COW; CROSS REACTION; DRUG INDICATION; DRUG SAFETY; EDEMA; EPIDEMIOLOGICAL DATA; EPISTAXIS; FIBRINOLYSIS; FOREIGN BODY REACTION; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM THROMBOSIS; HEMATOMA; HEMATOTHORAX; HEMATURIA; HUMAN; HYPERCOAGULABILITY; HYPOVOLEMIC SHOCK; HYPOXEMIA; INTRATHORACIC BLEEDING; LEUKOCYTOSIS; LIVER SURGERY; MEDIASTINUM HEMORRHAGE; MEDICAL LITERATURE; MEDLINE; MELENA; NASOPHARYNGEAL BLEEDING; PARTIAL NEPHRECTOMY; PARTIAL THROMBOPLASTIN TIME; PATIENT SAFETY; PELVIC BLEEDING; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE PERIOD; PROTEIN DEFICIENCY; PROTHROMBIN TIME; QUANTITATIVE ANALYSIS; REVIEW; SPINE SURGERY; THROMBIN TIME; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; UNSPECIFIED SIDE EFFECT; URINOMA; VASCULAR SURGERY; WOUND HEMATOMA;

ANIMALS; BIOLOGICAL MARKERS; CATTLE; HUMANS; THROMBIN; THROMBOPHILIA; TREATMENT OUTCOME;

EID: 51849133604     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.8.5.651     Document Type: Review

References (60)

1. Boldt J, Huttner I, Suttner S et al. Changes of haemostasis in patients undergoing major abdominal surgery - is there a difference between elderly and younger patients? Br. J. Anaesth. 87(3), 435-440 (2001).
2. Fareed J, Bick RL, Hoppensteadt DA, Bermes EW Jr. Molecular markers of hemostatic activation: applications in the diagnosis of thrombosis and vascular and thrombotic disorders. Clin. Appl. Thromb. Hemost. 1(2), 87-102 (1995). • Updates earlier work with an emphasis on hemostatic molecular markers. The author provides laboratory normals as well as changes expected in disease states such as pregnancy, atheroclerosis and sepsis/disseminated intravascular coagulation.
3. Whitton C, Sands D, Lee T, Chang A, Longstaff C. A reunification of the US ("NIH") and International Unit into a single standard for Thrombin. Thromb. Haemost. 93(2), 261-266 (2005).
4. Fareed J, Bick RL, Squillaci G, Walenga JM, Bermes EW Jr. Molecular markers of hemostatic disorders: implications in the diagnosis and therapeutic management of thrombotic and bleeding disorders. Clin. Chem. 29(9), 1641-1658 (1983). • Overview of hemostasis and thrombosis, complete with diagrams of all major component pathways. Markers are discussed as diagnostic tools.
5. Mann KG, Butenas S, Brummel K. The dynamics of thrombin formation. Arterioscler. Thromb. Vasc. Biol. 23(1), 17-25 (2003).
6. Lasne D, Jude B, Susen S. From normal to pathological hemostasis. Can. J. Anaesth. 53(6 Suppl.), S2-S11 (2006).
7. Ramachandran R, Hollenberg MD. Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more. Br. J. Pharmacol. 153(Suppl. 1), S263-S282 (2008).
8. Alving BM, Weinstein MJ, Finlayson JS, Menitove JE, Fratantoni JC. Fibrin sealant: summary of a conference on characteristics and clinical uses. Transfusion 35(9), 783-790 (1995).
9. Dorion RP, Hamati HF, Landis B et al. Risk and clinical significance of developing antibodies induced by topical thrombin preparations. Arch. Pathol. Lab. Med. 122(10), 887-894 (1998).
10. von Oppell UO, Zilla P. Tissue adhesives in cardiovascular surgery. J. Long Term Eff. Med. Implants 8(2), 87-101 (1998).
11. Mintz PD, Mayers L, Avery N et al. Fibrin sealant: clinical use and the development of the University of Virginia Tissue Adhesive Center. Ann. Clin. Lab. Sci. 31(1), 108-118 (2001).
12. Lundblad RL, Bradshaw RA, Gabriel D et al. A review of the therapeutic uses of thrombin. Thromb. Haemost. 91(5), 851-860 (2004). • Comprehensive review of thrombin as a biologic and as a therapy. Describes trends in adverse event reporting since its preclinical development in 1945.
13. Flaherty MJ, Wener MH. Antibodies to thrombin in postsurgical patients. Blood 73(5), 1386 (1989). • First author to propose that bovine thrombin product iatrogenic immunization is the mechanism of action of rare postoperative bleeds.
14. Streiff MB, Ness PM. Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure. Transfusion 42(1), 18-26 (2002).
15. Lee DI, Uribe C, Eichel L et al. Sealing percutaneous nephrolithotomy tracts with gelatin matrix hemostatic sealant: initial clinical use. J. Urol. 171(2 Pt 1), 575-578 (2004).
16. Milkes DE, Friedland S, Lin OS, Reid TR, Soetikno RM. A novel method to control severe upper GI bleeding from metastatic cancer with a hemostatic sealant: the CoStasis surgical hemostat. Gastrointest. Endosc. 55(6), 735-740 (2002).
17. Muntean W, Zenz W, Finding K, Zobel G, Beitzke A. Inhibitor to factor V after exposure to fibrin sealant during cardiac surgery in a two-year-old child. Acta Paediatr. 83(1), 84-87 (1994).
18. Crow SS, Sullivan VV, Aysola AE et al. Postoperative coagulopathy in a pediatric patient after exposure to bovine topical thrombin. Ann. Thorac. Surg. 83(4), 1547-1549 (2007).
19. Lawson JH, Lynn KA, Vanmatre RM et al. Antihuman factor V antibodies after use of relatively pure bovine thrombin. Ann. Thorac. Surg. 79(3), 1037-1038 (2005).
20. Flaherty MJ, Henderson R, Wener MH. Iatrogenic immunization with bovine thrombin: a mechanism for prolonged thrombin times after surgery. Ann. Intern. Med. 111(8), 631-634 (1989).
21. Neschis DG, Heyman MR, Cheanvechai V, Benjamin ME, Flinn WR. Coagulopathy as a result of factor V inhibitor after exposure to bovine topical thrombin. J. Vasc. Surg. 35(2), 400-402 (2002).
22. Kirkeby KM, Aronowitz P. Acquired factor V inhibitor: a common and avoidable complication of topical bovine thrombin application. Am. J. Med. 118(7), 805 (2005).
23. Winterbottom N, Kuo J, Nguyen K et al. Antigenic responses to bovine thrombin exposure during surgery: a prospective study of 309 patients. J. Applied Res. 2(1), 1-11 (2002).
24. The CoStasis Multi-center Collaborative Writing Committee. A novel collagenbased composite offers effective hemostasis for multiple surgical indications: results of a randomized controlled trial. Surgery 129(4), 445-450 (2001).
25. Kajitani M, Ozdemir A, Aguinaga M et al. Severe hemorrhagic complication due to acquired factor V inhibitor after single exposure to bovine thrombin product. J. Card. Surg. 15(6), 378-382 (2000).
26. Nelson PA, Powers JN, Estridge TD et al. Serological analysis of patients treated with a new surgical hemostat containing bovine proteins and autologous plasma. J. Biomed. Mater. Res. 58(6), 710-719 (2001).
27. Rapaport SI, Zivelin A, Minow RA, Hunter CS, Donnelly K. Clinical significance of antibodies to bovine and human thrombin and factor V after surgical use of bovine thrombin. Am. J. Clin. Pathol. 97(1), 84-91 (1992).
28. Warkentin TE, Greinacher A, Craven S et al. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation. Thromb. Haemost. 94(5), 958-964 (2005).
29. Greinacher A, Warkentin TE. The direct thrombin inhibitor hirudin. Thromb. Haemost. 99(5), 819-829 (2008).
30. Brennan M. Fibrin glue. Blood Rev. 5(4), 240-244 (1991).
31. Marques AC, Yu PC, Calderaro D, Gualandro DM, Caramelli B. High-risk patients undergoing major vascular surgery: to operate or not to operate? J. Am. Coll. Cardiol. 50(14), 1398-1399; author reply 1399 (2007).
32. Yau TM, Borger MA, Weisel RD, Ivanov J. The changing pattern of reoperative coronary surgery: trends in 1230 consecutive reoperations. J. Thorac. Cardiovasc. Surg. 120(1), 156-163 (2000). • More than 1000 patients were followed in a single hospital prospectively after reoperative coronary surgery for perioperative myocardial infarctions and postoperative death. Changes in patient risk profile and reoperation prevalence were noted from 1982 to 1997.
33. Weintraub WS, Jones EL, Craver JM, Grosswald R, Guyton RA. In-hospital and long-term outcome after reoperative coronary artery bypass graft surgery. Circulation 92(9 Suppl.), II50-II57 (1995).
34. Ofosu FA, Freedman J, Semple JW. Plasma-derived biological medicines used to promote haemostasis. Thromb. Haemost. 99(5), 851-862 (2008).
35. Desai SS, Massad MG, DiDomenico RJ et al. Recent developments in antithrombotic therapy: will sodium warfarin be a drug of the past? Recent Patents Cardiovasc. Drug Discov. 1(3), 307-316 (2006).
36. Martorell L, Martinez-Gonzalez J, Rodriguez C et al. Thrombin and protease-activated receptors (PARs) in atherothrombosis. Thromb. Haemost. 99(2), 305-315 (2008).
37. Sarfati MR, Dilorenzo DJ, Kraiss LW, Galt SW. Severe coagulopathy following intraoperative use of topical thrombin. Ann. Vasc. Surg. 18(3), 349-351 (2004).
38. Adams JD, Jones S, Brost BC. Development of antibodies to topical bovine thrombin after abdominal hysterectomy. A case report. J. Reprod. Med. 46(10), 909-912 (2001).
39. Zehnder JL, Leung LL. Immunological consequences of topical bovine thrombin. Am. J. Pathol. 159(6), 2371 (2001).
40. Christie RJ, Carrington L, Alving B. Postoperative bleeding induced by topical bovine thrombin: report of two cases. Surgery 121(6), 708-710 (1997).
41. Muntean W, Zenz W, Edlinger G, Beitzke A. Severe bleeding due to factor V inhibitor after repeated operations using fibrin sealant containing bovine thrombin. Thromb. Haemost. 77(6), 1223 (1997).
42. Chouhan VD, De La Cadena RA, Nagaswami C et al. Simultaneous occurrence of human antibodies directed against fibrinogen, thrombin, and factor V following exposure to bovine thrombin: effects on blood coagulation, protein C activation and platelet function. Thromb. Haemost. 77(2), 343-349 (1997).
43. Spero JA. Bovine thrombin-induced inhibitor of factor V and bleeding risk in postoperative neurosurgical patients. Report of three cases. J. Neurosurg. 78(5), 817-820 (1993).
44. Israels SJ, Israels ED. Development of antibodies to bovine and human factor V in two children after exposure to topical bovine thrombin. Am. J. Pediatr. Hematol. Oncol. 16(3), 249-254 (1994).
45. Cmolik BL, Spero JA, Magovern GJ, Clark RE. Redo cardiac surgery: late bleeding complications from topical thrombin-induced factor V deficiency. J. Thorac. Cardiovasc. Surg. 105(2), 222-227; discussion 227-228 (1993).
46. Banninger H, Hardegger T, Tobler A et al. Fibrin glue in surgery: frequent development of inhibitors of bovine thrombin and human factor V. Br. J. Haematol. 85(3), 528-532 (1993).
47. Stricker RB, Lane PK, Leffert JD et al. Development of antithrombin antibodies following surgery in patients with prosthetic cardiac valves. Blood 72(4), 1375-1380 (1988).
48. Carroll JF, Moskowitz KA, Edwards NM et al. Immunologic assessment of patients treated with bovine fibrin as a hemostatic agent. Thromb. Haemost. 76(6), 925-931 (1996).
49. Mohler ER III, Mitchell ME, Carpenter JP et al. Therapeutic thrombin injection of pseudoaneurysms: a multicenter experience. Vasc. Med. 6(4), 241-244 (2001).
50. Richter F, Schnorr D, Deger S et al. Improvement of hemostasis in open and laparoscopically performed partial nephrectomy using a gelatin matrix-thrombin tissue sealant (FloSeal). Urology 61(1), 73-77 (2003).
51. Vannorsdall MD, Arkel YS, Ku DH, Lucas FL, Himmelfarb J. Perioperative topical bovine thrombin exposure is not associated with hemodialysis graft thrombosis. Kidney Int. 64(2), 690-696 (2003).
52. Gill IS, Ramani AP, Spaliviero M et al. Improved hemostasis during laparoscopic partial nephrectomy using gelatin matrix thrombin sealant. Urology 65(3), 463-466 (2005).
53. Schoenecker JG, Hauck RK, Mercer MC, Parker W, Lawson JH. Exposure to topical bovine thrombin during surgery elicits a response against the xenogeneic carbohydrate galactose a1-3galactose. J. Clin. Immunol. 20(6), 434-444 (2000).
54. Ortel TL, Mercer MC, Thames EH, Moore KD, Lawson JH. Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann. Surg. 233(1), 88-96 (2001). • Prospective study of 151 cardiac patients who were assayed before and after surgery for topical thrombin, factor V, factor Va, prothrombin and thrombin. Although this paper was the best in measuring and displaying individual titers, its lack of thrombin exposure quantization was typical of other papers.
55. Fastenau DR, McIntyre JA. Immunochemical analysis of polyspecific antibodies in patients exposed to bovine fibrin sealant. Ann. Thorac. Surg. 69(6), 1867-1872 (2000).
56. McNeil NL, Clark TW. Sonographically guided percutaneous thrombin injection versus sonographically guided compression for femoral artery pseudoaneurysms. AJR Am. J. Roentgenol. 176(2), 459-462 (2001).
57. Barret JP, Dziewulski P, Wolf SE et al. Effect of topical and subcutaneous epinephrine in combination with topical thrombin in blood loss during immediate near-total burn wound excision in pediatric burned patients. Burns 25(6), 509-513 (1999).
58. Mathiasen RA, Cruz RM. Prospective, randomized, controlled clinical trial of a novel matrix hemostatic sealant in children undergoing adenoidectomy. Otolaryngol. Head Neck Surg. 131(5), 601-605 (2004).
59. Mathiasen RA, Cruz RM. Prospective, randomized, controlled clinical trial of a novel matrix hemostatic sealant in patients with acute anterior epistaxis. Laryngoscope 115(5), 899-902 (2005).
60. Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler. Thromb. Vasc. Biol. 27(8), 1687-1693 (2007).